AZD8055

Name: AZD8055
Brand: Selleck Chemicals
SKU: S1555
Rating: 5 (119 reviews)

For research use only. Not for use in humans.

Catalog No.S1555

119 publications

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Selleck's AZD8055 has been cited by 119 publications

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Nat Med, 2017, 23(2):200-212

PubMed: 28067899 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):177-190

PubMed: 27939219 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):255-63

PubMed: 25564516 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):245-54

PubMed: 25564517 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Autophagy, 2019, 15(3):543-557

PubMed: 30269645 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5107-5121

PubMed: 31164374 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Sci Signal, 2019, 12(612)

PubMed: 31848319 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627299 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):366-377

PubMed: 30661989 ( click the link to review the publication )
Am J Cancer Res, 2019, 9(9):1922-1937

PubMed: 31598395 ( click the link to review the publication )

Sci Rep, 2019, 9(1):30

PubMed: 30631106 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

Cancer Gene Ther, 2019, 10.1038/s41417-019-0117-7

PubMed: 31257364 ( click the link to review the publication )

Biochem J, 2019, 476(20):3081-3107

PubMed: 31665227 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:5196028

PubMed: 31223619 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):21-36

PubMed: 30831322 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):465-478

PubMed: 29593330 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(8):1338-1346

PubMed: 29345254 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2735-2743

PubMed: 29720580 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):632-642

PubMed: 29928450 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2207

PubMed: 29263324 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )
Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2017, 1864(10):1554-1565

PubMed: 28641977 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Anticancer Res, 2017, 37(3):1083-1090

PubMed: 28314268 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41422-41431

PubMed: 28507282 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(5):527-39

PubMed: 27043084 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(1):22-8

PubMed: 26595461 ( click the link to review the publication )

EMBO J, 2016, 35(17):1902-22

PubMed: 27481935 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):538-52

PubMed: 26686971 ( click the link to review the publication )

J Biol Chem, 2016, 291(12):6262-71

PubMed: 26755732 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

Cell Signal, 2016, 28(4):284-93

PubMed: 26795954 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1515-20

PubMed: 27565731 ( click the link to review the publication )

Int J Endocrinol, 2016, 2016:5286972

PubMed: 27990160 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Autophagy, 2015, 11(2):285-97

PubMed: 25801301 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

Sci Signal, 2015, 8(375):ra42

PubMed: 25943352 ( click the link to review the publication )
Clin Sci (Lond), 2015, 128(8):517-26

PubMed: 25428582 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2014, 10(6):1120-36

PubMed: 24879157 ( click the link to review the publication )

Leukemia, 2014, 28(5):1092-102

PubMed: 24135829 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(22):5756-67

PubMed: 25316808 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )
Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

Oncol Rep, 2014, 31(2):649-56

PubMed: 24297300 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

J Hypertens, 2013, 31(2):303-11

PubMed: 23303355 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Onco Targets Ther, 2013, 6:1373-84

PubMed: 24124380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\4R2tKSzVyPUCuNFI{OzFizszN	Mk\mV2FPT0WU
NCI-H720	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTBwMEK5N\|gh\|ryP	M17ZW3NCVkeHUh?=
KARPAS-45	M1fFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfqRYRNUUN3ME2wMlA{OzdzIN88US=>	NWS5NXM{W0GQR1XS
EW-3	M4PJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTBwMESwOVYh\|ryP	NHH4[FZUSU6JRWK=
SBC-1	NGrhZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzofHJ1UUN3ME2wMlA1PThzIN88US=>	M3\jVHNCVkeHUh?=
NCI-H209	NVrkZXpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnKcI9KSzVyPUCuNFU1PTNizszN	NF3pZ\|lUSU6JRWK=
EoL-1-cell	NVyyNnE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnT0TWM2OD1yLkC2OVY6KM7:TR?=	NIjiTW5USU6JRWK=
H9	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Hte2lEPTB;MD6wOlY6OiEQvF2=	M4XGPHNCVkeHUh?=
AN3-CA	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnBTWM2OD1yLkC3PVUyKM7:TR?=	Mn;HV2FPT0WU
HH	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwMEiwNFkh\|ryP	MkO0V2FPT0WU
KU812	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLWVo5CUUN3ME2wMlA5ODR\|IN88US=>	NYOxdVBSW0GQR1XS
DU-4475	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XMUmlEPTB;MD6wPFA1PyEQvF2=	Ml24V2FPT0WU
CTV-1	NEizSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfITWM2OD1yLkC4OlQyKM7:TR?=	MkLGV2FPT0WU
BV-173	M2Lh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTBwMEmwOlEh\|ryP	MWPTRW5ITVJ?
ES5	MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HnUWlEPTB;MD6wPVM2KM7:TR?=	M3\MRXNCVkeHUh?=
G-402	NIf2bHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLKTYhOUUN3ME2wMlA6QThizszN	MoHuV2FPT0WU
MV-4-11	NWj2bYxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETCN4pKSzVyPUCuNVA{PDdizszN	M3ThUHNCVkeHUh?=
NB69	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTBwMUO1JO69VQ>?	MV3TRW5ITVJ?
EGI-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfxUIZJUUN3ME2wMlE{PTNzIN88US=>	Mn3NV2FPT0WU
EW-18	M4n6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILXZlJKSzVyPUCuNVQxPzNizszN	NF7SUolUSU6JRWK=
ME-180	NH7Qc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDmZmRKSzVyPUCuNVQ3QDFizszN	NYjyNWFuW0GQR1XS
D-283MED	NXTMc\|U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmWyTWM2OD1yLkG0O\|I{KM7:TR?=	Ml\PV2FPT0WU
NB14	NUHoOI5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTIXYJKSzVyPUCuNVY1PDdizszN	MnP4V2FPT0WU
Ramos-2G6-4C10	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTBwMU[5PFMh\|ryP	MnvoV2FPT0WU
NBsusSR	NGHIUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwMUewNVkh\|ryP	M{fkS3NCVkeHUh?=
LAMA-84	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37oV2lEPTB;MD6xPFA{OiEQvF2=	NInYWoZUSU6JRWK=
NCI-H1581	NEP4[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTBwMUi5OlYh\|ryP	MojjV2FPT0WU
A204	M{LETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3u3[2lEPTB;MD6xPFk4KM7:TR?=	NHXnVpFUSU6JRWK=
A549	NH7YTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPVPIJwUUN3ME2wMlE6PTVizszN	MljUV2FPT0WU
CAL-51	NH;yNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLXOHZKSzVyPUCuNVk3PTFizszN	M17PSnNCVkeHUh?=
NKM-1	NXnZV5V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILDcJFKSzVyPUCuNlAxOjlizszN	NV\EbVJlW0GQR1XS
LoVo	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzpWZhKSzVyPUCuNlAzODJizszN	NYTPW2xGW0GQR1XS
HAL-01	M37UNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjaTWM2OD1yLkKwNlk4KM7:TR?=	NYPPXGl1W0GQR1XS
HCC2218	NHzvSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTBwMkC2PFgh\|ryP	NEi1dpFUSU6JRWK=
BEN	NVu2bmdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT2VVNuUUN3ME2wMlIyOjl\|IN88US=>	MnvIV2FPT0WU
LC-2-ad	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX2wV3JxUUN3ME2wMlIzODh2IN88US=>	M3;jOnNCVkeHUh?=
LXF-289	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rJT2lEPTB;MD6yOVA1OSEQvF2=	NGnNVFNUSU6JRWK=
HGC-27	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljMTWM2OD1yLkK2OFE1KM7:TR?=	NI\WflBUSU6JRWK=
LK-2	M4fWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXhUpRKSzVyPUCuNlY5OjRizszN	M2r6VHNCVkeHUh?=
CTB-1	MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fxO2lEPTB;MD6yO\|IyPSEQvF2=	Ml7WV2FPT0WU
697	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTBwMkezOlch\|ryP	MX\TRW5ITVJ?
ES7	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTBwMkezPFMh\|ryP	MlKyV2FPT0WU
MG-63	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL4OGl3UUN3ME2wMlI4PDB5IN88US=>	Mn\RV2FPT0WU
T47D	NWn1PIhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwMke0O\|Uh\|ryP	NHzJe5hUSU6JRWK=
RPMI-8226	M1TkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml[5TWM2OD1yLkK4OVg6KM7:TR?=	NUH5b2MxW0GQR1XS
NCI-H292	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPlW5NKSzVyPUCuNlkyPjRizszN	NHzH[\|hUSU6JRWK=
HT	Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\lSGVKSzVyPUCuNlk{QCEQvF2=	MoCyV2FPT0WU
A3-KAW	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTBwMkm3OEDPxE1?	NVvYUnhpW0GQR1XS
LB2241-RCC	MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTBwM{CxPVgh\|ryP	MXvTRW5ITVJ?
BB65-RCC	NXTMZZJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nuc2lEPTB;MD6zNFgxPSEQvF2=	NXHGOoRMW0GQR1XS
G-401	NXX1VJBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTBwM{C5PFYh\|ryP	MoLrV2FPT0WU
TYK-nu	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXLR4FXUUN3ME2wMlMyQDZ2IN88US=>	MXzTRW5ITVJ?
NCI-SNU-1	MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTBwM{KzN\|Eh\|ryP	NIKyTIxUSU6JRWK=
CHL-1	NUHGdZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPCe5FIUUN3ME2wMlMzPzB\|IN88US=>	MVfTRW5ITVJ?
P30-OHK	NYfHbnF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHpTWM2OD1yLkOyO\|A2KM7:TR?=	NF;IcnpUSU6JRWK=
PA-1	M3Htd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTBwM{O2NVkh\|ryP	MX\TRW5ITVJ?
LB1047-RCC	NVz5OY51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfZ[GtTUUN3ME2wMlM1ODR5IN88US=>	NH7rUJRUSU6JRWK=
EM-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELUUWNKSzVyPUCuN\|QyQDhizszN	NVvaRmNxW0GQR1XS
VA-ES-BJ	NI\QSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfZblhKSzVyPUCuN\|QzPjhizszN	M4PCRnNCVkeHUh?=
NCI-H520	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwM{S4N\|Qh\|ryP	NYn4Z2xDW0GQR1XS
ECC10	M2XkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLENFZKSzVyPUCuN\|UxOzVizszN	MWLTRW5ITVJ?
LNCaP-Clone-FGC	NYK5XoVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3sSXR[UUN3ME2wMlM2OzF2IN88US=>	NX;tPGluW0GQR1XS
ES8	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTBwM{[1OVMh\|ryP	NVTHNZoyW0GQR1XS
HuO-3N1	NGW0SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTBwM{izO\|kh\|ryP	MUDTRW5ITVJ?
L-363	NGLQ[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX5TWM2OD1yLkO5NFI3KM7:TR?=	MljIV2FPT0WU
SK-LU-1	MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jaN2lEPTB;MD6zPVIxQCEQvF2=	MnvYV2FPT0WU
MCF7	NFS5dmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rSd2lEPTB;MD60NFU{KM7:TR?=	NUDufWFrW0GQR1XS
HuO9	NXm5Sm1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3r2SGlEPTB;MD60NFY3PyEQvF2=	NWTTdZc2W0GQR1XS
BHT-101	NFLxeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofUTWM2OD1yLkSwO\|g4KM7:TR?=	NXzO[\|ZIW0GQR1XS
MZ2-MEL	M1;keGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDWN4k2UUN3ME2wMlQxQDh{IN88US=>	NGjp[ZVUSU6JRWK=
NOS-1	M2L1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTBwNEGwO\|Qh\|ryP	MUTTRW5ITVJ?
NEC8	NF3y[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGP5R41KSzVyPUCuOFE3QTVizszN	MUfTRW5ITVJ?
COR-L88	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4KwcmlEPTB;MD60NlI3PyEQvF2=	M{XCO3NCVkeHUh?=
MFM-223	NVO1SGMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGizUG9KSzVyPUCuOFI3OTdizszN	M4rOdXNCVkeHUh?=
HSC-3	NHu3N3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4S0OGlEPTB;MD60NlkxQCEQvF2=	MkTvV2FPT0WU
OVCAR-5	MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVy1[HlxUUN3ME2wMlQzQTN\|IN88US=>	MoXlV2FPT0WU
MFE-280	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofkTWM2OD1yLkSzNFMzKM7:TR?=	Ml\CV2FPT0WU
KP-N-YS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTBwNEOwO{DPxE1?	NFnNXoZUSU6JRWK=
EPLC-272H	MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\VOnFKSzVyPUCuOFMxPzdizszN	NGjrZ4FUSU6JRWK=
KE-37	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTBwNEOyOFch\|ryP	MmfVV2FPT0WU
HuH-7	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYewSos5UUN3ME2wMlQ{Ozd{IN88US=>	NF36RZNUSU6JRWK=
CHP-212	M1PUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEL1[JlKSzVyPUCuOFM3QTdizszN	MlTUV2FPT0WU
SK-MES-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHf2c5hKSzVyPUCuOFM5PDhizszN	M3XhS3NCVkeHUh?=
SJSA-1	Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3O5Z2lEPTB;MD60OFU2PCEQvF2=	MkTTV2FPT0WU
QIMR-WIL	MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\GUFdKSzVyPUCuOFUyPSEQvF2=	M1r6NHNCVkeHUh?=
ES4	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLse2ZKSzVyPUCuOFU{OzZizszN	M4PLTXNCVkeHUh?=
TI-73	NHOzTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTBwNEW2PFYh\|ryP	NVnwNpRrW0GQR1XS
COLO-684	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmS0TWM2OD1yLkS1O\|I3KM7:TR?=	M3[zTXNCVkeHUh?=
GCIY	NWPa[oxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnhWndKSzVyPUCuOFU4PTRizszN	MonaV2FPT0WU
JVM-3	NVuyd2NWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTw[FhOUUN3ME2wMlQ3Ojl{IN88US=>	NHnCdGJUSU6JRWK=
MPP-89	M1TmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4X5ZmlEPTB;MD60Olk1PyEQvF2=	MUfTRW5ITVJ?
M14	NH3mcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHjRlBHUUN3ME2wMlQ4OTdizszN	NY\t[YtLW0GQR1XS
SW962	NIrjO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\XW\|BUUUN3ME2wMlQ4OTlizszN	NUTWVop6W0GQR1XS
VM-CUB-1	Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M132WGlEPTB;MD60O\|I5PiEQvF2=	MXXTRW5ITVJ?
A101D	M4m1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTBwNEi5Olgh\|ryP	NFzWcoVUSU6JRWK=
DB	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDNTWM2OD1yLkWwNFIyKM7:TR?=	MUPTRW5ITVJ?
KNS-62	M{DFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vSeGlEPTB;MD61NFU3QCEQvF2=	NHu2dmxUSU6JRWK=
NCI-H460	NILXN\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTBwNUC1PVch\|ryP	NH:4TnJUSU6JRWK=
MDA-MB-361	NH;aR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXwbVVKSzVyPUCuOVA5PyEQvF2=	MlXaV2FPT0WU
DOK	NIjneI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoH2TWM2OD1yLkWxN\|M{KM7:TR?=	M3XQVXNCVkeHUh?=
CAL-39	NEHveXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPUTWM2OD1yLkWyNlY5KM7:TR?=	NXX4NJdsW0GQR1XS
HT-1080	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rtb2lEPTB;MD61NlU1OyEQvF2=	NFzrO2tUSU6JRWK=
GR-ST	M1PuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PXW2lEPTB;MD61N\|AyPSEQvF2=	NVTJem04W0GQR1XS
J-RT3-T3-5	M1;ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjYTJkyUUN3ME2wMlU{OTl3IN88US=>	MV\TRW5ITVJ?
NCI-H1793	MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvXTWM2OD1yLkWzOFQ4KM7:TR?=	NUeydZY1W0GQR1XS
NCI-H1355	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPucnM4UUN3ME2wMlU{QDd6IN88US=>	NXHQe3dQW0GQR1XS
YH-13	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fDfGlEPTB;MD61OFk{QCEQvF2=	M2\GRXNCVkeHUh?=
LOXIMVI	NFjDdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLNTWM2OD1yLkW1NVI{KM7:TR?=	NVfOSmxKW0GQR1XS
ES1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrPXW02UUN3ME2wMlU2PTF6IN88US=>	M1XxOHNCVkeHUh?=
GAMG	NXnYe\|k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7VcXVSUUN3ME2wMlU2PjV6IN88US=>	NInvbYdUSU6JRWK=
SK-MEL-28	NFHad2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVOxZmdIUUN3ME2wMlU2QTFizszN	M1zjXXNCVkeHUh?=
KG-1	NFPP[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7LPGJzUUN3ME2wMlU3QDh2IN88US=>	MX;TRW5ITVJ?
HOS	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nVTWlEPTB;MD61O\|E6OiEQvF2=	M{mybXNCVkeHUh?=
PANC-08-13	NEfPPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTBwNUezPFkh\|ryP	M2q5O3NCVkeHUh?=
SW780	NVvWd3Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTBwNUe1PVUh\|ryP	NFTSPHFUSU6JRWK=
MDA-MB-175-VII	Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXS1OoNLUUN3ME2wMlU4PzRzIN88US=>	Ml72V2FPT0WU
MSTO-211H	NF;2dZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIn4cWRKSzVyPUCuOVc4PTFizszN	MYDTRW5ITVJ?
ML-2	NICxcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILPNWVKSzVyPUCuOVg1PzhizszN	MoP5V2FPT0WU
SCC-4	NFvRZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3vTWM2OD1yLkW4OVQyKM7:TR?=	NGTFPZhUSU6JRWK=
NCI-H1048	M4DhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrSWnVKSzVyPUCuOVg3PDVizszN	M{XVXHNCVkeHUh?=
NCI-H28	NIf4TWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzLOmVKSzVyPUCuOVg3PzVizszN	MkjoV2FPT0WU
BCPAP	NGjVboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlntTWM2OD1yLkW4O\|kyKM7:TR?=	M1zIR3NCVkeHUh?=
PC-14	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LOPWlEPTB;MD61PFk4KM7:TR?=	M3rrTHNCVkeHUh?=
OAW-42	MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3G2WmlEPTB;MD61PVE3OiEQvF2=	MlSyV2FPT0WU
IA-LM	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPSeFFKSzVyPUCuOVk3ODlizszN	MWPTRW5ITVJ?
Hs-578-T	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTBwNUm4OVEh\|ryP	MnnqV2FPT0WU
H4	NYPySHhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nmb2lEPTB;MD62NFA6PCEQvF2=	MnPHV2FPT0WU
HL-60	M{DSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fG[mlEPTB;MD62NFM2OSEQvF2=	NFTPNpZUSU6JRWK=
NCI-H1437	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYn2eIRTUUN3ME2wMlYxPjF7IN88US=>	MV\TRW5ITVJ?
KGN	MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\Xb3ZKSzVyPUCuOlExPDlizszN	M{LyXXNCVkeHUh?=
NCI-H2452	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4X2VWlEPTB;MD62NVkyPyEQvF2=	NGHySJJUSU6JRWK=
BFTC-905	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkO0TWM2OD1yLk[yNVI3KM7:TR?=	NWj1bY5nW0GQR1XS
CAMA-1	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTBwNkKxOVIh\|ryP	MX\TRW5ITVJ?
SK-NEP-1	M{fRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLpe2lZUUN3ME2wMlYzPTB{IN88US=>	M3OycXNCVkeHUh?=
NCI-H522	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnRNGlKSzVyPUCuOlI6QTJizszN	NVHTZmNiW0GQR1XS
SW1710	NX;WbZhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXwR\|RbUUN3ME2wMlY{OTZ5IN88US=>	Mnv3V2FPT0WU
RVH-421	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv4TWM2OD1yLk[zOlM6KM7:TR?=	MWHTRW5ITVJ?
SK-MEL-2	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\RfGlEPTB;MD62OFE2OyEQvF2=	NIPkb5hUSU6JRWK=
KYSE-150	MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;0VWlEPTB;MD62OlE5PiEQvF2=	NXnTOXB[W0GQR1XS
MOLT-13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17ZdGlEPTB;MD62OlU{PyEQvF2=	M{[1[XNCVkeHUh?=
SK-OV-3	NWXud4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;nN4pKSzVyPUCuOlcyQDdizszN	M1L3VXNCVkeHUh?=
IGROV-1	NGnqSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rZTGlEPTB;MD62O\|Q2KM7:TR?=	NYDEOJZQW0GQR1XS
MOLT-4	NYH4Z4dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvocYRKSzVyPUCuOlc3QDlizszN	MUnTRW5ITVJ?
MEL-HO	NFHSOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXSTWM2OD1yLk[3O\|UzKM7:TR?=	M1rEdXNCVkeHUh?=
MDA-MB-157	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTBwNke4NUDPxE1?	MUTTRW5ITVJ?
MN-60	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml[xTWM2OD1yLk[3PFQ3KM7:TR?=	M1HVUnNCVkeHUh?=
EFO-27	M1nLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTBwNke5O\|kh\|ryP	MmLqV2FPT0WU
HO-1-N-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfxSFNKSzVyPUCuOlgxPjRizszN	MmCwV2FPT0WU
TE-5	NHLt[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\oOodtUUN3ME2wMlY5PDB3IN88US=>	M4CyNHNCVkeHUh?=
EW-22	NFTaN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmS3TWM2OD1yLk[4OFQ1KM7:TR?=	M1fH[3NCVkeHUh?=
SW982	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHNTWM2OD1yLk[4OVAyKM7:TR?=	Mm\oV2FPT0WU
SF295	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnh[GpXUUN3ME2wMlY5PTB5IN88US=>	M1S4S3NCVkeHUh?=
WM-115	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HyRmlEPTB;MD62PFkzPCEQvF2=	M3;sUXNCVkeHUh?=
COLO-800	NE\EeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEf2fmRKSzVyPUCuOlk5OTNizszN	NXvGWWNwW0GQR1XS
NTERA-S-cl-D1	NF65cpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\NTWM2OD1yLkewNFY{KM7:TR?=	M{OzT3NCVkeHUh?=
NCI-H1648	MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTBwN{CxO\|Mh\|ryP	NHf1c3hUSU6JRWK=
NB5	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoCwTWM2OD1yLkewN\|E6KM7:TR?=	M1z1fXNCVkeHUh?=
ATN-1	NXTNcmZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnYTWM2OD1yLkewOVkh\|ryP	MXnTRW5ITVJ?
NUGC-3	NWHlXI9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XSZmlEPTB;MD63NFY6OSEQvF2=	NHjve3BUSU6JRWK=
22RV1	NWrHVHNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXPWmdRUUN3ME2wMlcxPzF5IN88US=>	MkLXV2FPT0WU
8305C	NEP1dZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHXTWM2OD1yLkewO\|U2KM7:TR?=	MYjTRW5ITVJ?
EFM-19	M4jESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDE[o86UUN3ME2wMlcxQDR5IN88US=>	MYTTRW5ITVJ?
PC-3	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTBwN{KyN{DPxE1?	MXfTRW5ITVJ?
C32	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;PTWM2OD1yLkeyOFg1KM7:TR?=	M3rP[HNCVkeHUh?=
MC-IXC	M2j1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfGdIhPUUN3ME2wMlczPzF6IN88US=>	MlLTV2FPT0WU
OMC-1	NFT0PWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTBwN{K3N\|gh\|ryP	M2WxTHNCVkeHUh?=
HTC-C3	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fa[2lEPTB;MD63N\|E4OiEQvF2=	NVPKb2cxW0GQR1XS
RPMI-7951	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfISoZKSzVyPUCuO\|M2OzNizszN	MWDTRW5ITVJ?
AsPC-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvhTWM2OD1yLkezO\|k2KM7:TR?=	NIfuc5NUSU6JRWK=
CAKI-1	M37RPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fWXGlEPTB;MD63OFYzQSEQvF2=	Mn\3V2FPT0WU
MHH-PREB-1	NELTRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDqTWM2OD1yLke0O\|M3KM7:TR?=	NXHMUJFXW0GQR1XS
HLE	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jx[WlEPTB;MD63OFg1PCEQvF2=	NEDXN29USU6JRWK=
A375	M4nNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPLTWM2OD1yLke1NVk{KM7:TR?=	MlnhV2FPT0WU
RS4-11	NUjlNIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDwZphKSzVyPUCuO\|U6PDNizszN	M{TpZXNCVkeHUh?=
U-2-OS	M335[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTBwN{W5O{DPxE1?	NX7PT3hJW0GQR1XS
NCI-H747	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\HZmlEPTB;MD63OVk6OSEQvF2=	NUjESpV1W0GQR1XS
NCI-H1623	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{j3UWlEPTB;MD63OlI3OSEQvF2=	MVjTRW5ITVJ?
DMS-273	MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjDT5o4UUN3ME2wMlc3QTJ{IN88US=>	NHzjZY1USU6JRWK=
PSN1	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rDTmlEPTB;MD63O\|A2PyEQvF2=	MUHTRW5ITVJ?
LU-99A	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DjWGlEPTB;MD63O\|Y1QSEQvF2=	NXzzRVRXW0GQR1XS
CAL-12T	NUDJcVVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DrPGlEPTB;MD63PFAzQSEQvF2=	NYTvTJFzW0GQR1XS
KYSE-140	NWLGWlJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHITWM2OD1yLke4NVY5KM7:TR?=	MnPpV2FPT0WU
VMRC-RCZ	Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjJTWM2OD1yLke4OFgzKM7:TR?=	Mn3YV2FPT0WU
Ca9-22	NVL4TodRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfvTFZKSzVyPUCuO\|g4OzZizszN	NIHOe4pUSU6JRWK=
NCI-H1563	NH[0[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwN{i5NlYh\|ryP	NIi2VJdUSU6JRWK=
NCI-H650	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHH0U\|RKSzVyPUCuO\|kyPDRizszN	NFHaS2tUSU6JRWK=
DOHH-2	M3HCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1ixOGlEPTB;MD63PVM{KM7:TR?=	MnnJV2FPT0WU
OE33	NV7xcnU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDzZXdKSzVyPUCuO\|k6OTRizszN	MYHTRW5ITVJ?
CAL-62	NWnmZ4tDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTBwN{m5NlQh\|ryP	MoDyV2FPT0WU
NCI-H1770	NEPabXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHRNYk{UUN3ME2wMlgxOjFizszN	MWHTRW5ITVJ?
SN12C	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGf1WIdKSzVyPUCuPFA3PjhizszN	MmH1V2FPT0WU
HPAF-II	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XDWGlEPTB;MD64NFc6PCEQvF2=	MoTuV2FPT0WU
SNU-423	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzsNZlKSzVyPUCuPFE1OjJizszN	NXLmO3B5W0GQR1XS
A704	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPP[21KSzVyPUCuPFE4QThizszN	Moq4V2FPT0WU
OVCAR-4	Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1S5UWlEPTB;MD64NVkyOSEQvF2=	MXLTRW5ITVJ?
NCI-H2347	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTae2ZSUUN3ME2wMlgzPDBzIN88US=>	MlLyV2FPT0WU
OCUB-M	NWn1dldFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPHPY9KSzVyPUCuPFI3PzVizszN	MlfXV2FPT0WU
KYSE-450	NHm3bI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjsV5BKSzVyPUCuPFI4OjVizszN	NUi4UWo5W0GQR1XS
PFSK-1	Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTBwOEOwN\|kh\|ryP	M4PkWHNCVkeHUh?=
A431	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TET2lEPTB;MD64N\|EyPiEQvF2=	NITkWolUSU6JRWK=
MHH-ES-1	MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLL[INyUUN3ME2wMlg{PDV5IN88US=>	NXfDXWx4W0GQR1XS
HD-MY-Z	M{OzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH3bHZKSzVyPUCuPFQxQTJizszN	MWPTRW5ITVJ?
RT-112	NHvr[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC4epJKSzVyPUCuPFQ6OzdizszN	M3:5[3NCVkeHUh?=
KU-19-19	NXK1UGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXn1OVdoUUN3ME2wMlg2OTJzIN88US=>	NHj2ZotUSU6JRWK=
HCC1569	M3;XXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfYNJBKSzVyPUCuPFUzODdizszN	NWPxWZBoW0GQR1XS
RPMI-8866	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnH1TWM2OD1yLki1PFIzKM7:TR?=	M3\MdHNCVkeHUh?=
CAL-120	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPZUYNTUUN3ME2wMlg3ODRzIN88US=>	M4X0UHNCVkeHUh?=
CAL-33	NYG3PXN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXkRmc{UUN3ME2wMlg3PDl3IN88US=>	NVWxTI5tW0GQR1XS
RKO	NH7B[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7GPIJGUUN3ME2wMlg3QDF5IN88US=>	NXzrWWZiW0GQR1XS
HCC1419	NVnLd\|JYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfTTWM2OD1yLki2PVI5KM7:TR?=	NEnsd3BUSU6JRWK=
CP50-MEL-B	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIOzN3RKSzVyPUCuPFg{QDRizszN	NHXhU\|FUSU6JRWK=
BPH-1	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLpWpZrUUN3ME2wMlg5Ozl3IN88US=>	NFLueo5USU6JRWK=
SF126	NGTXbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTBwOEi3NVQh\|ryP	MlX3V2FPT0WU
BHY	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjnZolKSzVyPUCuPFg4OzRizszN	MkHmV2FPT0WU
BxPC-3	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTBwOEi4N\|Mh\|ryP	MYLTRW5ITVJ?
ETK-1	NGnxXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Xje2lEPTB;MD64PVM4OiEQvF2=	NXTlboNWW0GQR1XS
NCI-H1573	NVXVe4tnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwOUCyNlkh\|ryP	NEfCOpZUSU6JRWK=
C-33-A	NYrxSHdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XncmlEPTB;MD65NFQ1OiEQvF2=	Mmn4V2FPT0WU
UACC-893	NHTjdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1e2cGlEPTB;MD65Nlg2PSEQvF2=	NFPRd49USU6JRWK=
RXF393	NVHVdmluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zXfWlEPTB;MD65Nlg6PyEQvF2=	NVfQS2V2W0GQR1XS
MIA-PaCa-2	NWG3bWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4X5fWlEPTB;MD65NlkzOiEQvF2=	MnG5V2FPT0WU
HCC1806	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7qZ5RKSzVyPUCuPVMzPTZizszN	NXr4TnN5W0GQR1XS
DMS-114	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGCyRW5KSzVyPUCuPVM3PzdizszN	NXTWcXZZW0GQR1XS
MOLT-16	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTBwOUO4OFUh\|ryP	M3TT[nNCVkeHUh?=
ACN	NYDYTVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;Ic2lEPTB;MD65OFI4PyEQvF2=	NX;LPWkzW0GQR1XS
SNU-449	NH[2eW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnf4TWM2OD1yLkm1PVI1KM7:TR?=	NHfHVHZUSU6JRWK=
A427	NEjWWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTBwOU[xPVgh\|ryP	MljnV2FPT0WU
DEL	NVrq[oY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonRTWM2OD1yLkm2O\|c{KM7:TR?=	MmfCV2FPT0WU
NCI-H1792	NYPKc5pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fIWGlEPTB;MD65O\|ExOSEQvF2=	MYrTRW5ITVJ?
A2058	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPTUVhKSzVyPUCuPVc{PiEQvF2=	MnLUV2FPT0WU
SW13	Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGT3VpBKSzVyPUCuPVg{QTJizszN	NWn3SGVEW0GQR1XS
T98G	NUPTOW1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HOT2lEPTB;MT6wNVM3PCEQvF2=	NFToW4lUSU6JRWK=
LU-134-A	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1n2XmlEPTB;MT6wNlY4PSEQvF2=	MlPCV2FPT0WU
GI-ME-N	NILHXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXvTWM2OD1zLkCyPFI4KM7:TR?=	MX3TRW5ITVJ?
D-423MG	NVK2fIljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTFwMEK5OlMh\|ryP	NUfhSodPW0GQR1XS
PANC-03-27	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXtNGlKSzVyPUGuNFMyPDFizszN	MnLOV2FPT0WU
P12-ICHIKAWA	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTFwMEO0NFYh\|ryP	MnXGV2FPT0WU
SCH	NUT4NGtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\BSGlEPTB;MT6wN\|Q2KM7:TR?=	MmfvV2FPT0WU
D-566MG	MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TWcGlEPTB;MT6wOlczPiEQvF2=	NGPVSYFUSU6JRWK=
OS-RC-2	MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTFwMEe5OEDPxE1?	M1HhbHNCVkeHUh?=
KOSC-2	NHfxVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4D3R2lEPTB;MT6wPFAzOSEQvF2=	MXPTRW5ITVJ?
SH-4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mke1TWM2OD1zLkC4OFMyKM7:TR?=	MnzLV2FPT0WU
786-0	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWL5fXF4UUN3ME2xMlA5QTN2IN88US=>	MnL0V2FPT0WU
Mewo	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TkdWlEPTB;MT6wPVI1QCEQvF2=	NF[z[VFUSU6JRWK=
AGS	NF\XS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\mTWM2OD1zLkC5OFU6KM7:TR?=	NGrwZmlUSU6JRWK=
Daoy	NHewSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\NOmlEPTB;MT6wPVYzQCEQvF2=	NX7meZNTW0GQR1XS
SW48	NGDrelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLCdnF4UUN3ME2xMlExQTFzIN88US=>	MnrOV2FPT0WU
KYSE-180	NVn0XnhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVz3dJpuUUN3ME2xMlEyODJzIN88US=>	MY\TRW5ITVJ?
NH-12	NVnTXnpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVP5SpZkUUN3ME2xMlEyOjN5IN88US=>	M{PHWXNCVkeHUh?=
BE-13	M1v2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moi2TWM2OD1zLkGxO\|U6KM7:TR?=	MX7TRW5ITVJ?
ES3	NXPIV5FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTFwMUOxO\|Eh\|ryP	MX3TRW5ITVJ?
NCI-H1092	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrtTWM2OD1zLkGzOEDPxE1?	NGfu[3VUSU6JRWK=
NCI-H1755	M3jnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDQWHdKSzVyPUGuNVM6PDFizszN	NISydphUSU6JRWK=
EKVX	M{HwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzoTWM2OD1zLkG0NFAyKM7:TR?=	NWLMdnVyW0GQR1XS
NB13	M{PCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFwMUS0OUDPxE1?	MYTTRW5ITVJ?
NCI-H2405	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjmZlhSUUN3ME2xMlE1PTd2IN88US=>	NIq0WWZUSU6JRWK=
LS-411N	MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jGUmlEPTB;MT6xOVAyPyEQvF2=	Mo\0V2FPT0WU
MDA-MB-453	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{mzTWlEPTB;MT6xOVYzPCEQvF2=	MX7TRW5ITVJ?
SCC-15	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jEV2lEPTB;MT6xOlk2PiEQvF2=	NXzwW5dZW0GQR1XS
C2BBe1	M4PyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmr0TWM2OD1zLkG3NFU3KM7:TR?=	NIHxfopUSU6JRWK=
HT-144	NFLqRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTFwMUewO{DPxE1?	M17aRnNCVkeHUh?=
HEC-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTFwMUe2Nlch\|ryP	MlG3V2FPT0WU
HCE-T	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPjXoEyUUN3ME2xMlE4QTh\|IN88US=>	MlPIV2FPT0WU
IST-MEL1	MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL6XHMxUUN3ME2xMlE6ODh{IN88US=>	NGO2OXpUSU6JRWK=
Detroit562	NELBNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rUTmlEPTB;MT6xPVQ{QSEQvF2=	M4mwZ3NCVkeHUh?=
A4-Fuk	NIrhcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTFwMkC0OFEh\|ryP	NVr2V3VjW0GQR1XS
HDLM-2	NX7wWpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO3TWM2OD1zLkKxN\|I3KM7:TR?=	NG\s[JVUSU6JRWK=
MKN7	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXxTWM2OD1zLkKxO\|AzKM7:TR?=	NVf4cGtqW0GQR1XS
MDA-MB-415	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4ntV2lEPTB;MT6yNVcxOiEQvF2=	NFTRWotUSU6JRWK=
BT-20	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nBRmlEPTB;MT6yNlQ1PCEQvF2=	NUDV[lZJW0GQR1XS
NCI-H2030	M{G4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTFwMkSxNFYh\|ryP	M33RdXNCVkeHUh?=
LS-123	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTFwMkS3OVMh\|ryP	NEjWRYFUSU6JRWK=
SK-MEL-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3WOnhKSzVyPUGuNlQ4PzZizszN	MWPTRW5ITVJ?
KS-1	MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NET4U2lKSzVyPUGuNlUyPzFizszN	M{DsNHNCVkeHUh?=
LU-65	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPTeoNkUUN3ME2xMlI2PjB4IN88US=>	NV;3O3hMW0GQR1XS
NCI-H596	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXzTWM2OD1zLkK1PVI6KM7:TR?=	MkPsV2FPT0WU
KYSE-410	NHnsSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTFwMkewNVQh\|ryP	NWiwblR6W0GQR1XS
NCI-H2228	NEfTRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTJWFZRUUN3ME2xMlI4OTZ5IN88US=>	NVTLW5drW0GQR1XS
LN-405	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vSR2lEPTB;MT6yPFAzOSEQvF2=	NHnVclZUSU6JRWK=
8505C	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTFwMki4NlMh\|ryP	MXzTRW5ITVJ?
BFTC-909	MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTFwMkm0N\|Qh\|ryP	M{XVW3NCVkeHUh?=
OC-314	MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHMTWM2OD1zLkK5PVI6KM7:TR?=	MYXTRW5ITVJ?
NMC-G1	NXnMRm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPQTWM2OD1zLkOxNVM2KM7:TR?=	MXHTRW5ITVJ?
SKG-IIIa	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTwTWM2OD1zLkOxOFI5KM7:TR?=	NGP2SlJUSU6JRWK=
GAK	NG\vRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTFwM{G4OVgh\|ryP	NYjCfmc5W0GQR1XS
D-263MG	NEfRUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\5TWM2OD1zLkOyOlQyKM7:TR?=	MXnTRW5ITVJ?
NCI-H446	NWTwV2ljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTEVppKSzVyPUGuN\|I6ODJizszN	MljkV2FPT0WU
TGBC1TKB	NXi0e5pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy1fZJKSzVyPUGuN\|I6QThizszN	MWfTRW5ITVJ?
GCT	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\ZTWM2OD1zLkO0N\|Q2KM7:TR?=	NYjWWZZ[W0GQR1XS
COR-L23	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTLc\|lNUUN3ME2xMlM1QDR3IN88US=>	NV2wbIM{W0GQR1XS
TK10	Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXITWM2OD1zLkO1O\|k4KM7:TR?=	M3;EdHNCVkeHUh?=
ES6	M1TNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{G5O2lEPTB;MT6zOlM4PiEQvF2=	MYfTRW5ITVJ?
SW1088	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorNTWM2OD1zLkO2OlEzKM7:TR?=	M1;WUnNCVkeHUh?=
AM-38	NEPzemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEL4NJRKSzVyPUGuN\|cyQTlizszN	MnPoV2FPT0WU
CHP-134	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\BdGlEPTB;MT6zO\|g1PCEQvF2=	NXnlb\|JLW0GQR1XS
SW872	NHmxcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFwM{i1OVUh\|ryP	NITYUIVUSU6JRWK=
LB831-BLC	NVXYc49{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XpNGlEPTB;MT6zPVA3PyEQvF2=	MlrEV2FPT0WU
TE-12	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTFwNEC2NFEh\|ryP	MlfrV2FPT0WU
LCLC-97TM1	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\LOlJKSzVyPUGuOFExPDZizszN	M{PqS3NCVkeHUh?=
HCT-116	NIe0UphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWj1b3BCUUN3ME2xMlQzQDV2IN88US=>	NX\IdJgyW0GQR1XS
ALL-PO	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXe0UWs3UUN3ME2xMlQ{Pzd2IN88US=>	NYnXVoZHW0GQR1XS
EW-16	NWjWZXByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFwNEO4OFIh\|ryP	Mn7JV2FPT0WU
NCI-H661	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFwNES3O\|Uh\|ryP	NGTCSpRUSU6JRWK=
TE-8	NVnhfI5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFwNEW1OkDPxE1?	MnjqV2FPT0WU
TCCSUP	NFTveXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFwNE[5OkDPxE1?	NITjWJdUSU6JRWK=
SW1990	NHzFfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTFwNEe1N\|Mh\|ryP	M3GzbHNCVkeHUh?=
UM-UC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLGNoVGUUN3ME2xMlQ4Pjd3IN88US=>	M{DVfXNCVkeHUh?=
HuP-T4	NXTT[Zd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTFwNEi2NFch\|ryP	MlfEV2FPT0WU
NCI-H1299	NI\BeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\5SFhKSzVyPUGuOVAxQDZizszN	M4XYdHNCVkeHUh?=
RO82-W-1	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTwTWM2OD1zLkWyNFgyKM7:TR?=	MlX6V2FPT0WU
Becker	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3z2eWlEPTB;MT61NlE5PyEQvF2=	Mlj0V2FPT0WU
SNU-387	NIqxUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPhRotKSzVyPUGuOVIzPDFizszN	M2rvNXNCVkeHUh?=
CAL-85-1	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTQTWM2OD1zLkWyOVk6KM7:TR?=	MYjTRW5ITVJ?
647-V	NF30WZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DVRWlEPTB;MT61N\|g5KM7:TR?=	NUfubWJVW0GQR1XS
SBC-5	M3H3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXwTWM2OD1zLkW0OVk{KM7:TR?=	NFLuNIFUSU6JRWK=
NCI-H23	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwNUW3NVQh\|ryP	MX7TRW5ITVJ?
CGTH-W-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DNS2lEPTB;MT61OVgyQSEQvF2=	MWjTRW5ITVJ?
SK-N-FI	NXm0[HlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHmzeW1KSzVyPUGuOVU6ODhizszN	MVHTRW5ITVJ?
KM-H2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjmeI1KSzVyPUGuOVY1PzRizszN	M2DUeHNCVkeHUh?=
KY821	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULHOolWUUN3ME2xMlU3PjF5IN88US=>	NI\NW3ZUSU6JRWK=
RH-1	NY\Dfo9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvUfFNCUUN3ME2xMlU3PzZ{IN88US=>	NVH1R5hMW0GQR1XS
KYSE-270	MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTzfoNKSzVyPUGuOVc1OjNizszN	NHvDRmVUSU6JRWK=
SF539	NU\aUodpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFwNUe5Olkh\|ryP	M3rNfHNCVkeHUh?=
JEG-3	NHPwN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zkcmlEPTB;MT61PFA6PCEQvF2=	MV\TRW5ITVJ?
SCC-25	NX7Eco1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvNTWM2OD1zLkW4OFMzKM7:TR?=	NU\jdnFQW0GQR1XS
SW1573	NVrKfGNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXLWWE3UUN3ME2xMlYxOTV6IN88US=>	MmTMV2FPT0WU
EW-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYG0ZYVRUUN3ME2xMlYyOzVzIN88US=>	MV;TRW5ITVJ?
YKG-1	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTFwNkG0N\|gh\|ryP	MVHTRW5ITVJ?
EW-11	Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnIXYhKSzVyPUGuOlE4PDFizszN	MmHVV2FPT0WU
DJM-1	M1nyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFwNkG4NlUh\|ryP	NFLVNWNUSU6JRWK=
Calu-3	M2TPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M363fWlEPTB;MT62OVIyOyEQvF2=	MmPWV2FPT0WU
HT-3	MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXniTINLUUN3ME2xMlY2PjZizszN	M13YeHNCVkeHUh?=
NCI-H69	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1f3N2lEPTB;MT62O\|M1OyEQvF2=	MlTuV2FPT0WU
NCI-H2126	M4XFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DzOGlEPTB;MT62O\|c6PyEQvF2=	NFq4b5dUSU6JRWK=
RPMI-2650	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGm3TWVKSzVyPUGuOlg{OTdizszN	NUHCRXBmW0GQR1XS
TE-6	MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Pt[2lEPTB;MT63NFg4PCEQvF2=	Mn65V2FPT0WU
MDA-MB-231	M2H1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTFwN{G5PVMh\|ryP	NXXuVnNvW0GQR1XS
A2780	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTFwN{KyNFch\|ryP	MlrjV2FPT0WU
GOTO	NGLIOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTFwN{O1OkDPxE1?	NUTFNFh6W0GQR1XS
KYSE-70	NH;zUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jPfGlEPTB;MT63OFQ1OiEQvF2=	MX\TRW5ITVJ?
GMS-10	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTFwN{S2OlIh\|ryP	M360[HNCVkeHUh?=
CaR-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mke3TWM2OD1zLke0PFEzKM7:TR?=	NXPBTHlUW0GQR1XS
SW900	Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTFwN{S5PVMh\|ryP	M3TPW3NCVkeHUh?=
BB49-HNC	M4nKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\uTWM2OD1zLke1NVY5KM7:TR?=	MYLTRW5ITVJ?
SNB75	M3LmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\jTWM2OD1zLke1OFkzKM7:TR?=	NWfW[VduW0GQR1XS
SK-PN-DW	NUe0S2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LOfWlEPTB;MT63OVY5OiEQvF2=	MnHUV2FPT0WU
5637	NH7SWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13ySGlEPTB;MT63O\|I3QCEQvF2=	NVXJ[I8zW0GQR1XS
BT-474	NIPL[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoT2TWM2OD1zLke4NVcyKM7:TR?=	M1\ZdHNCVkeHUh?=
KM12	M2PtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[yUXRlUUN3ME2xMlc6PzRzIN88US=>	M{faNHNCVkeHUh?=
COLO-680N	M{PCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrzb5hKSzVyPUGuPFI{QDFizszN	NYrlWZNvW0GQR1XS
Saos-2	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTFwOEK0OFUh\|ryP	MlrmV2FPT0WU
CAL-54	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEK1c2ZKSzVyPUGuPFM{OTNizszN	M1f3dXNCVkeHUh?=
U-118-MG	NETZeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\UcnVKSzVyPUGuPFQ3OjJizszN	NYPBclZoW0GQR1XS
TGBC24TKB	NHLEe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fJeWlEPTB;MT64OVUxOSEQvF2=	NF[wc5pUSU6JRWK=
NCI-H2052	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vVOWlEPTB;MT64OlQyKM7:TR?=	NEPTe3FUSU6JRWK=
BB30-HNC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPURWNKSzVyPUGuPFY1PjJizszN	M3LN[nNCVkeHUh?=
KNS-81-FD	M3vtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37EWmlEPTB;MT64PVE3PSEQvF2=	NXLWPJA1W0GQR1XS
HN	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;ZNIJHUUN3ME2xMlg6PTR3IN88US=>	NIrxd2dUSU6JRWK=
ACHN	Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1:5OWlEPTB;MT65NFc5PiEQvF2=	Mm[zV2FPT0WU
HSC-2	NF33R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTFwOUGwPVYh\|ryP	MnzIV2FPT0WU
HCC2998	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTFwOUOzNlUh\|ryP	M3HZWXNCVkeHUh?=
HEL	M4\H[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTFwOUSxPFQh\|ryP	NUDo[I01W0GQR1XS
SW684	MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nyOmlEPTB;MT65O\|M4OSEQvF2=	NF7mNFhUSU6JRWK=
NCI-H1693	NXHh[HVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\CfGlEPTB;MT65PFA5PiEQvF2=	MmDoV2FPT0WU
8-MG-BA	M3WwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXaZ3FkUUN3ME2xMlk5OjFizszN	M1;vfnNCVkeHUh?=
OVCAR-8	NWDDNIJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoCwTWM2OD1{LkCwNlk2KM7:TR?=	MY\TRW5ITVJ?
DSH1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\yNWNKSzVyPUKuNFE4PzRizszN	MX3TRW5ITVJ?
KYSE-520	NFjNbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTJwMEKwOFkh\|ryP	NWTFU2gyW0GQR1XS
GB-1	NFjIPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJwMEK1O\|ch\|ryP	NFrONoZUSU6JRWK=
RCC10RGB	MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3qySmlEPTB;Mj6wOFg4OSEQvF2=	M1v5O3NCVkeHUh?=
SW954	NEjXWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILvO29KSzVyPUKuNFUxOzZizszN	MWPTRW5ITVJ?
IST-MES1	NHz2UGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTJwMEW1Olgh\|ryP	M4H5T3NCVkeHUh?=
AU565	NX;JfpNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP3TWM2OD1{LkC1PVA2KM7:TR?=	MnXGV2FPT0WU
CW-2	M3LsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJwME[4O\|Uh\|ryP	NITq[lZUSU6JRWK=
TE-1	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTJwMEmzO\|ch\|ryP	NFHNNlNUSU6JRWK=
KP-4	NXL5ZWNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7JZ3U4UUN3ME2yMlExOzF{IN88US=>	MnTIV2FPT0WU
SNU-C2B	NVfwRWxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrsOWt[UUN3ME2yMlExQDJ\|IN88US=>	NFrtRo9USU6JRWK=
NCI-H1395	MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljBTWM2OD1{LkGwPVg3KM7:TR?=	NWr3WmV{W0GQR1XS
CAS-1	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jYPWlEPTB;Mj6xNVU1PiEQvF2=	MlLaV2FPT0WU
NCI-H1155	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTJwMkK2PUDPxE1?	NWfxN2lbW0GQR1XS
SK-MEL-1	NXXsVXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\B[WlEPTB;Mj6yPFE5OSEQvF2=	MnvnV2FPT0WU
KINGS-1	M13vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LyUmlEPTB;Mj6zNFA5QCEQvF2=	MYTTRW5ITVJ?
ESS-1	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\KdIF6UUN3ME2yMlMxPTFizszN	MkTmV2FPT0WU
PANC-10-05	M{fqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\4TWM2OD1{LkO3NFI1KM7:TR?=	MonIV2FPT0WU
HT-1376	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;2ZWlEPTB;Mj6zPFcxQCEQvF2=	MWPTRW5ITVJ?
LS-513	M4TmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTJwM{i4O\|Qh\|ryP	M4[0O3NCVkeHUh?=
KNS-42	NGDsSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HsSmlEPTB;Mj6zPVExPSEQvF2=	NF3ScWdUSU6JRWK=
639-V	M{HUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTJwNEK3OVgh\|ryP	Mnf3V2FPT0WU
SJRH30	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjuTWM2OD1{LkS1NVYyKM7:TR?=	NIewbWdUSU6JRWK=
SW1783	M{jwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmj0TWM2OD1{LkS3NFc5KM7:TR?=	M{[1[HNCVkeHUh?=
NB6	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLjUJJRUUN3ME2yMlQ5OjhizszN	MkW0V2FPT0WU
SK-MEL-30	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJwNEi4N{DPxE1?	M37IU3NCVkeHUh?=
HCE-4	M2myfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJwNEm0NFIh\|ryP	MlHTV2FPT0WU
NB10	NH;tPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[5[mlEPTB;Mj60PVQzQSEQvF2=	NVHJS24zW0GQR1XS
H-EMC-SS	M{LQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF[4V2hKSzVyPUKuOVQ3PSEQvF2=	MnfRV2FPT0WU
SK-HEP-1	NWDhZWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7aTWM2OD1{LkW1NlM3KM7:TR?=	NFey[lVUSU6JRWK=
HCC1395	NFfzRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmWyTWM2OD1{LkW1OlU2KM7:TR?=	MmTHV2FPT0WU
HuCCT1	M3XuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHRXm9KSzVyPUKuOVY{QSEQvF2=	M17XdnNCVkeHUh?=
SiHa	NHviNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJwNUi3NVkh\|ryP	M4DYfXNCVkeHUh?=
EFO-21	NXLFTYh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1r1[mlEPTB;Mj61PFc3PCEQvF2=	M4H1bHNCVkeHUh?=
NCI-H1666	NFzx[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LSXWlEPTB;Mj61PVA4PiEQvF2=	MW\TRW5ITVJ?
UMC-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXYTWM2OD1{LkW5PFY5KM7:TR?=	NVXjOGt1W0GQR1XS
COLO-679	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2O4e2lEPTB;Mj62NVI{OyEQvF2=	MnK1V2FPT0WU
A388	NV72NnZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4r2[WlEPTB;Mj62OVI2OyEQvF2=	Mnm5V2FPT0WU
LB2518-MEL	M4L6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mli1TWM2OD1{Lk[1OFA5KM7:TR?=	MmPoV2FPT0WU
EW-13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGC2R\|BKSzVyPUKuOlg4PjhizszN	MlOwV2FPT0WU
MLMA	NVTSTZM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfGTWM2OD1{Lk[4PFU3KM7:TR?=	NYrzbVFpW0GQR1XS
HOP-92	NXTI[3YxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkm4TWM2OD1{LkewNVEh\|ryP	MYfTRW5ITVJ?
NOMO-1	Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPkb4xKSzVyPUKuO\|E1PDJizszN	NULKXHBNW0GQR1XS
NCI-H810	NFPOTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGq0cXZKSzVyPUKuO\|IyQThizszN	NHf5WnZUSU6JRWK=
769-P	M1zSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTJwN{KyPEDPxE1?	NIXTdm9USU6JRWK=
SAS	M4T3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HENmlEPTB;Mj63OlUh\|ryP	MlPVV2FPT0WU
M059J	NV7MR\|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILkO\|hKSzVyPUKuO\|g{OThizszN	NF;KRpNUSU6JRWK=
RD	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofGTWM2OD1{Lke5OFcyKM7:TR?=	NI\PZoRUSU6JRWK=
GT3TKB	NEnPb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\0cWlEPTB;Mj64N\|Q{OyEQvF2=	NX74dm5YW0GQR1XS
MZ7-mel	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW[yOFBUUUN3ME2yMlg3PTB{IN88US=>	MWTTRW5ITVJ?
KYSE-510	NY[3[G9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJwOEm1NFQh\|ryP	NYrISW5rW0GQR1XS
NCI-N87	Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37aRWlEPTB;Mj65NVgxPyEQvF2=	M3n6ZXNCVkeHUh?=
MKN1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkH5TWM2OD1\|LkCwNVY{KM7:TR?=	MlnRV2FPT0WU
NCI-H2170	NV\VNWU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTNwMEC0OVEh\|ryP	MWjTRW5ITVJ?
OVCAR-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXf5O3BIUUN3ME2zMlAzOTF3IN88US=>	NGPETY5USU6JRWK=
KLE	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fpTGlEPTB;Mz6wOlgyOiEQvF2=	NEXC[2RUSU6JRWK=
LB771-HNC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTUTWM2OD1\|LkC5N\|Q{KM7:TR?=	M3HFcXNCVkeHUh?=
MC116	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLvOJlVUUN3ME2zMlEyOTF{IN88US=>	M3mwUHNCVkeHUh?=
SCC-9	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHXPXFKSzVyPUOuNVE{PjZizszN	NETHXnBUSU6JRWK=
U031	MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonBTWM2OD1\|LkGyOFI{KM7:TR?=	NHXiZWxUSU6JRWK=
LCLC-103H	M3:5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDobGpKSzVyPUOuNlM5QTRizszN	MUfTRW5ITVJ?
U-266	M4LmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXocGh3UUN3ME2zMlI4PjN\|IN88US=>	NF3ve4lUSU6JRWK=
JVM-2	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\IeG1KSzVyPUOuN\|IyPjRizszN	NW\0TnpNW0GQR1XS
UACC-257	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MniyTWM2OD1\|LkS2OFMyKM7:TR?=	MnXxV2FPT0WU
LB996-RCC	M4nt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4mySWlEPTB;Mz60OlUxOiEQvF2=	MlP1V2FPT0WU
BT-549	M{DoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXINmxKSzVyPUOuOVAzODlizszN	M{HEcXNCVkeHUh?=
NCI-H526	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17VeWlEPTB;Mz61OFE2QCEQvF2=	MYrTRW5ITVJ?
RH-18	NYDqVVU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTNwNkG3PVgh\|ryP	NGO0TG1USU6JRWK=
SW626	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTNwN{GxNlgh\|ryP	NHvaNHRUSU6JRWK=
SK-N-AS	NWridWpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHnXpdKSzVyPUOuO\|MzPDdizszN	NUfne3pCW0GQR1XS
IGR-1	MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjtdYRGUUN3ME2zMlc1OjR6IN88US=>	NHyxO\|dUSU6JRWK=
NCI-H2291	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv4TWM2OD1\|Lke1N\|M3KM7:TR?=	MoXSV2FPT0WU
NCI-H441	NWTZSY86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrjTWM2OD1\|LkiyOFM{KM7:TR?=	M1rlU3NCVkeHUh?=
D-247MG	MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTNwOE[wN\|Eh\|ryP	M2rLOXNCVkeHUh?=
COLO-320-HSR	MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTNwOUGyO\|Eh\|ryP	MW\TRW5ITVJ?
A253	NXTyZplmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTNwOUG0N\|Yh\|ryP	M3\MO3NCVkeHUh?=
HT55	Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3n1dmlEPTB;Mz65NVc4OyEQvF2=	MWPTRW5ITVJ?
MZ1-PC	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3u2OmlEPTB;Mz65OVg3PCEQvF2=	MXrTRW5ITVJ?
RERF-LC-MS	NVfxNoRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTNwOU[1NlUh\|ryP	Mn72V2FPT0WU
SF268	NUPJVowzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHIVnNbUUN3ME20MlEzQDhzIN88US=>	NHnORY9USU6JRWK=
RMG-I	M3fJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTRwMkG0OVQh\|ryP	MYLTRW5ITVJ?
CFPAC-1	NGH0[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXZT4VKSzVyPUSuNlE3QDVizszN	MoDSV2FPT0WU
S-117	NH;L[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37ERmlEPTB;ND6yNlAzPCEQvF2=	MVLTRW5ITVJ?
NCI-H2122	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTRwM{C5N\|Eh\|ryP	NIHVRmJUSU6JRWK=
J82	M{DwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XlTmlEPTB;ND6zN\|Q1OSEQvF2=	NY\VZ49wW0GQR1XS
CAL-72	NF;wOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfjXIk6UUN3ME20MlM2PDd5IN88US=>	MUHTRW5ITVJ?
GP5d	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7kfItKSzVyPUSuOFEzQThizszN	NYnpV28{W0GQR1XS
UACC-62	NH:2[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEm2[plKSzVyPUSuOFY2PDVizszN	NI\LRZpUSU6JRWK=
MS-1	NVPaXohKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorKTWM2OD12LkS5NVE2KM7:TR?=	NX3qXFl6W0GQR1XS
RCM-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTRwNUK5NkDPxE1?	NXi4cVFGW0GQR1XS
IST-SL1	M17nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HZ[mlEPTB;ND62OVM2QSEQvF2=	MU\TRW5ITVJ?
SW756	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVP5XHhoUUN3ME20MlY6OTN3IN88US=>	M2C0OXNCVkeHUh?=
HCC38	M4nuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTRwN{GxPVch\|ryP	M2Hve3NCVkeHUh?=
YAPC	M3zRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3BfnNKSzVyPUSuO\|E{OTNizszN	MlLZV2FPT0WU
DK-MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\DO3pKSzVyPUSuO\|gyOTJizszN	MkjEV2FPT0WU
HCC1937	NHnpU\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LrdGlEPTB;ND64OVEzPSEQvF2=	MmrVV2FPT0WU
OAW-28	M{ixd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTpfoVKSzVyPUSuPVI1OzVizszN	MVfTRW5ITVJ?
MEG-01	NXzxSWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTVwMEizNlgh\|ryP	MYTTRW5ITVJ?
GI-1	NEHMb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TI[WlEPTB;NT6yN\|Q5PiEQvF2=	M3jYdHNCVkeHUh?=
FADU	M1PzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TudWlEPTB;NT6yO\|g{PyEQvF2=	NXHwbZNUW0GQR1XS
CAPAN-1	M4jIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLEdXhrUUN3ME21MlM6PDN{IN88US=>	M2HtSHNCVkeHUh?=
TGBC11TKB	MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3EWYJPUUN3ME21MlQ2Pzh4IN88US=>	M3r0THNCVkeHUh?=
DBTRG-05MG	NUO1VXNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\meYVKSzVyPUWuOVA2OiEQvF2=	M1v6eXNCVkeHUh?=
ONS-76	M171Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoiyTWM2OD13LkW1PFAyKM7:TR?=	NEjIVYFUSU6JRWK=
Ca-Ski	MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTSNHVHUUN3ME21MlYzPTZ4IN88US=>	MUPTRW5ITVJ?
COLO-741	MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\ROHJHUUN3ME21MlcyQTl3IN88US=>	MUPTRW5ITVJ?
HT-29	MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnGTWM2OD13LkiwOFc2KM7:TR?=	MWrTRW5ITVJ?
HCC1187	NVjoXFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnm3TWM2OD13LkixNFA5KM7:TR?=	NYLYd2NXW0GQR1XS
Capan-2	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInEOWlKSzVyPUWuPVU6QTRizszN	NV;1XmZHW0GQR1XS
NCI-H630	NFn0[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;R[2lEPTB;Nj6xNVQ1OSEQvF2=	NIr3SlFUSU6JRWK=
COLO-678	M{LiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnBTWM2OD14LkG1NFkzKM7:TR?=	M3fGTHNCVkeHUh?=
D-502MG	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnmWGlKSzVyPU[uNVc{OzZizszN	MY\TRW5ITVJ?
NB17	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjo[GlKSzVyPU[uNlQ6PDNizszN	M2jUd3NCVkeHUh?=
SK-MEL-24	M33kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTZwMk[0PUDPxE1?	NV;hWnBnW0GQR1XS
NCI-SNU-5	M2\6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXK[GhKSzVyPU[uNlcyOThizszN	MoLPV2FPT0WU
D-392MG	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PPNGlEPTB;Nj6zN\|M6QSEQvF2=	M3jOdXNCVkeHUh?=
A498	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;RTWM2OD14LkSwN\|AzKM7:TR?=	MXrTRW5ITVJ?
OCI-AML2	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTwTWM2OD14LkS1OFQ2KM7:TR?=	MV3TRW5ITVJ?
HCC2157	NHzXclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTZwNEW2NVYh\|ryP	M4nIUnNCVkeHUh?=
C3A	MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjjXo9KSzVyPU[uOVIxODRizszN	M1;G[3NCVkeHUh?=
NCI-H1650	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTZwN{C1NlIh\|ryP	NV3MepBtW0GQR1XS
DU-145	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTZwN{ewN{DPxE1?	NGTEWpNUSU6JRWK=
COLO-829	Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XjV2lEPTB;Nj63O\|g4OyEQvF2=	M1LNb3NCVkeHUh?=
LS-1034	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVL4[JM5UUN3ME23MlA1PDF{IN88US=>	MmfYV2FPT0WU
HCC1954	M1Htd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TVVGlEPTB;Nz60PFE{PCEQvF2=	NHHpRoZUSU6JRWK=
KURAMOCHI	M2rmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\WOoJKSzVyPUeuOFg2OzNizszN	NXHSUYgyW0GQR1XS
Mo-T	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPBSWZKSzVyPUeuOVE1QThizszN	MYTTRW5ITVJ?
OE19	M1GyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnyeVJDUUN3ME23MlY2PTB\|IN88US=>	MVLTRW5ITVJ?
COR-L105	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTWTWM2OD15LkexOFIyKM7:TR?=	NY\NVXJZW0GQR1XS
NCI-H2342	NVzYbnViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnuZmJyUUN3ME23MlcyPTJzIN88US=>	MkfGV2FPT0WU
U-87-MG	NVH5c41jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\Re49TUUN3ME24MlA{OzN2IN88US=>	MkSzV2FPT0WU
MKN28	MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHITWM2OD16LkGxOVE2KM7:TR?=	M1TheXNCVkeHUh?=
HT-1197	NHLwbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfxeFFKSzVyPUiuNlU6ODdizszN	M1TmPXNCVkeHUh?=
ChaGo-K-1	NHTxNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPpVXJ[UUN3ME24MlM1OjR3IN88US=>	Mmi4V2FPT0WU
NCI-H226	NYXOWJJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HhTGlEPTB;OD60OFM{OSEQvF2=	M2\DfXNCVkeHUh?=
NCI-H2029	M3HYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fxXmlEPTB;OT6wOlc2QSEQvF2=	NFrqUldUSU6JRWK=
TE-11	NULYXGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DQUGlEPTB;OT60OVU5QCEQvF2=	MVnTRW5ITVJ?
ZR-75-30	NVnk[FA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3ofJhKSzVyPUmuPVI3OzRizszN	MWnTRW5ITVJ?
SW837	NGX2T4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTFyLkKyPVMh\|ryP	NIrEfldUSU6JRWK=
NCI-H1651	MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7mTWM2OD1zMD6yN\|I3KM7:TR?=	MmXTV2FPT0WU
NCI-H727	NH\0Ro1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\WRoxKSzVyPUGwMlQ1QTVizszN	Ml7YV2FPT0WU
NCI-H358	NVTXbod7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfMT5B1UUN3ME2xNE45OzZ3IN88US=>	NVLRUlhzW0GQR1XS
NCI-H2087	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vBS2lEPTB;MUGuNFQ{PCEQvF2=	MYLTRW5ITVJ?
FTC-133	NU\LWXV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTFzLkSwOVEh\|ryP	MXHTRW5ITVJ?
LAN-6	NIXIdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rWNmlEPTB;MUKuNVI1KM7:TR?=	NYC4bXd2W0GQR1XS
NCI-H1838	M37ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NICzNmJKSzVyPUGyMlUyPTFizszN	M37tNXNCVkeHUh?=
Calu-6	M17CSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnxeI1KSzVyPUG0MlExOjFizszN	M2DUO3NCVkeHUh?=
HCC70	NEHHSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF2LkS1NUDPxE1?	MXLTRW5ITVJ?
KARPAS-299	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHrWGtKSzVyPUG1MlIyPTlizszN	M3;OT3NCVkeHUh?=
CAL-27	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnTTWM2OD1zNT6zPFQ{KM7:TR?=	MlHoV2FPT0WU
NCI-H82	NGjiNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;vOGhKSzVyPUG1MlU{OiEQvF2=	M1PBSXNCVkeHUh?=
no-10	NHXSNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2ruN2lEPTB;MUWuPVM5KM7:TR?=	NHWyTJpUSU6JRWK=
U251	NXfYRVV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzMTWM2OD1zNj6zOlc2KM7:TR?=	MYXTRW5ITVJ?
TE-9	NIe2T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHlO4t3UUN3ME2xO{42OTZ4IN88US=>	NGnlZXRUSU6JRWK=
TE-10	NX;jZWVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfyfmxKSzVyPUG5MlA3ODdizszN	MnnGV2FPT0WU
COLO-824	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXiTWM2OD1{MD65Nlc3KM7:TR?=	NH;WT41USU6JRWK=
HuP-T3	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETKN\|NKSzVyPUKxMlA4PDhizszN	NUTKb2ZDW0GQR1XS
KALS-1	M3m2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETzeXJKSzVyPUKxMlE4PSEQvF2=	MVPTRW5ITVJ?
L-428	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPITWM2OD1{MT60NFE3KM7:TR?=	NEXEcJRUSU6JRWK=
JAR	M2P6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTsTWM2OD1{MT61NFIh\|ryP	NFfpSG1USU6JRWK=
DoTc2-4510	M122dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LoeWlEPTB;MkOuPFQ4PSEQvF2=	MVXTRW5ITVJ?
ABC-1	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHnTWM2OD1{Nj63PVU4KM7:TR?=	MXvTRW5ITVJ?
MHH-NB-11	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTN\|LkO0OlQh\|ryP	MWHTRW5ITVJ?
SW1463	M3LHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHq0NpRKSzVyPUOzMlk5OyEQvF2=	MlTVV2FPT0WU
SW1417	NXPVO5N7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDmZotKSzVyPUO3MlA6PTJizszN	MlPkV2FPT0WU
NB12	M1X2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\ad2lEPTB;M{muOFY2PSEQvF2=	MkXOV2FPT0WU
NY	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DGSmlEPTB;NEGuN\|IxOSEQvF2=	MWnTRW5ITVJ?
H1048	NE\NRoxCeG:ydH;zbZMhSXO\|YYm=	M1GwNlUxOCCwTR?=	Ml;DO\|IhcA>?		NXvGTYJ4dmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	NY\kcnR[OjV5M{e1OFI>
H86	M{XTWmFxd3C2b4Ppd{BCe3OjeR?=	MmC4OVAxKG6P	MWW3NkBp		M1HV[Y5p[W6lZYOgRWJVNTJ4M,MAl4lv\HWlZXSgZZBweHSxc3nz	NXHu[IZxOjV5M{e1OFI>
H196	NYS3dVBGSXCxcITvd4l{KEG\|c3H5	M4nP[lUxOCCwTR?=	M4\LTlczKGh?		NFPlOWJvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	MkH4NlU4Ozd3NEK=
H446	NGjtdZJCeG:ydH;zbZMhSXO\|YYm=	NWDMXnRmPTByIH7N	M2nOTVczKGh?		Ml3ycohidmOnczDBRnQuOjZ\|4pETbY5lfWOnZDDhdI9xfG:\|aYO=	MlK5NlU4Ozd3NEK=
TFK-1	NIHve\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{[0TlczKGh?	MU\EUXNQ	NWT0dI5sUUN3ME20O{BvVQ>?	MYWyOVE2OjJ2NB?=
EGI-1	M{X0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnexO\|IhcA>?	Mn;0SG1UVw>?	NIDhNFVKSzVyPUWzJI5O	M2T6e\|I2OTV{MkS0
OCI/AML3	M4\2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mln2NE4zKM7:TR?=	MVi0PEBp		NGf6[mNmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgd4VtfW2ndHnubYI>	NWT6fZFEOjR5M{mzPVM>
U937	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DiNlAvOiEQvF2=	MVq0PEBp		MUflcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	NYrLV3R3OjR5M{mzPVM>
MOLM13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmD0NE4zKM7:TR?=	MnTaOFghcA>?		NGnDWHJmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgd4VtfW2ndHnubYI>	NI[5b2szPDd\|OUO5Ny=>
MCF7	MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjhNlAhdk1?	MYe3NkBp	MWjGRnM>	MofCdoVlfWOnczD0bIUhWEWOUEGtcYVlcWG2ZXSgbY5kemWjc3WgbY4h[2WubDD2bYFjcWyrdIm=	M{X3flI1Pjh6MES2
TamR	M13Vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnpZodmUUN3ME2xPQKBkW6P	NXzTb\|FYOjR2NUewOlk>
MCF7-X	MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTJ2IH7N	MXuyOFQ2PzB4OR?=
T47D-tamR	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljYTWM2OD1zOTDuUS=>	MUOyOFQ2PzB4OR?=
293T	MmDhSpVv[3Srb36gRZN{[Xl?	MX[yNEBvVQ>?	M{D1O\|MhcA>?		Mn;E[Il{enWydIOgRYt1NW2nZHnheIVlKFSLRj3JRUB{fGGkaXzpeJktKHS{YX7zcI9k[XSrb36sJIFv\CCjY4Tpeol1gQ>?	NHHGUIMzPDN4M{S0PS=>
SW620	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPFflBQOC5yMEGtNVDPxE1?	MYOyOEBp		M1zwSolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYOgeIhmKGOxbnPlcpRz[XSrb36gdol{\XN?	NVPPZ3p5OjR\|NkO0OFk>
Huh7	NWGxbXJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvPTIUxPS1zMECgcm0>	MU[wMVI1KGh?	MmraSG1UVw>?	NXrENXVFcW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	M{G2NVI1Ojl5M{Cw
Hep3B	NHfzcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofDOU0yODBibl2=	MUmwMVI1KGh?	NVTPeGtnTE2VTx?=	MVjpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	M{CydVI1Ojl5M{Cw
Huh7	MUDGeY5kfGmxbjDBd5NigQ>?	MkWzNVAxKG6P	NGXDfpgyOiCq	MV\EUXNQ	MnH3bY5lfWOnczDheZRweGijZ4pCpC=>	MVmyOFI6PzNyMB?=
U87-MG	NGDnZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoTsO\|IhcA>?		NGrRbGlIUTVy4pEJQgKBkTd7IH7NxsA>	M{PwOFI1OjR7NkSw
L3.6pl	NWnCSpA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PnNFEh\|ryP	M2i2dFczKGh?		NUDE[W1qcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwdWKrbnXkJJdqfGhiQl3TMVc4PzZyNx?=	MnKxNlQzOzN\|OUm=
TE671	MkLURZBweHSxc3nzJGF{e2G7	NWniRWhiOSEQvF2=	MXG0PEBp		NEPCfmZqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	MUGyOFE{OzJzOB?=
RD	NHzJdIRCeG:ydH;zbZMhSXO\|YYm=	NVH3dmJYOSEQvF2=	M3TkTVQ5KGh?		MYrpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDBRnQuPzN5	NVWySWs3OjRzM{OyNVg>
RMS13	M37ZfmFxd3C2b4Ppd{BCe3OjeR?=	MVyxJO69VQ>?	MnrIOFghcA>?		MmjLbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	MYCyOFE{OzJzOB?=
RH30	MX7BdI9xfG:\|aYOgRZN{[Xl?	MWKxJO69VQ>?	M4[5WlQ5KGh?		MYTpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDBRnQuPzN5	NUPCToJzOjRzM{OyNVg>
Hep-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XUT\|AvODFvMTFOwG0>	Ml64NVIuQTZiaB?=		NHu2[IRqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	Ml;SNlQyODN5NEm=
SCC-9	M1rUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPyNE4xOS1zIN88US=>	NFLkVJQyOi17NjDo		MlH0bY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NYDmNZE2OjRzMEO3OFk>
Hep-2	MXHGeY5kfGmxbjDBd5NigQ>?	NXjGbphvOC5zL{CuOUDPxE1?	MmjPNlQhcA>?		M3y3S4Jtd2OtczDtWG9TSzFiYX7kJI1VV1KFMjDhZ5RqfmG2aX;u	MkHzNlQyODN5NEm=
SCC-9	MkDoSpVv[3Srb36gRZN{[Xl?	NU\hXmtlOC5zL{CuOUDPxE1?	NHzBcIIzPCCq		NUXRSG45[myxY3vzJI1VV1KFMTDhcoQhdVSRUlOyJIFkfGm4YYTpc44>	NETGfZczPDFyM{e0PS=>
PANC-1	MVrBdI9xfG:\|aYOgRZN{[Xl?	NFHlR5E2ODBibl2=	NEHqd2Y1QCCq		M3XUSpNmdnOrdHn6[ZMheGGwY4LlZZRq[yClYX7j[ZIh[2WubIOgeI8hemGmaX;0bIVz[XC7	M2XwNVI{QDh4Mkm0
RMG2	M3G4[mFxd3C2b4Ppd{BCe3OjeR?=	M{[5UVEuOTByMDDuUS=>	MVm3NkBp	NEDvSmxHSlN?	Ml\YbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	NInSXYszOzZzNU[zNS=>
HAC2	M3rLSmFxd3C2b4Ppd{BCe3OjeR?=	NVfQV5pQOS1zMECwJI5O	NUT2W2ZWPzJiaB?=	MoLGSmJU	NX7EflJWcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	M4jSblI{PjF3NkOx
HT-29	MYXBdI9xfG:\|aYOgRZN{[Xl?	MmHlNUDPxE1?	NV;kUphvPzJiaB?=		NHv0VVJifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	M{K0WVIyQTR7MUKx
DLD1	NYTRT4twSXCxcITvd4l{KEG\|c3H5	NX;zfFI2OSEQvF2=	NUnGdndrPzJiaB?=		NUH4fVRm[XS2ZX71ZZRmeyB3LV\VMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	MXuyNVk1QTF{MR?=
HT-29	M3L6O2Z2dmO2aX;uJGF{e2G7	MXSxJO69VQ>?	NHvtR3Q4OiCq		M2LRWYlv\HWlZYOgZZV1d3CqYXf5JJRwKGOxbn\ldkBkgXSxcILveIVkfGmxbh?=	MnHENlE6PDlzMkG=
DLD1	NEnlSXZHfW6ldHnvckBCe3OjeR?=	NFrtd24yKM7:TR?=	MonMO\|IhcA>?		MlTobY5lfWOnczDheZRweGijZ4mgeI8h[2:wZnXyJIN6fG:ycn;0[YN1cW:w	MUiyNVk1QTF{MR?=
Rh41	M1;uRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XlNWlEPTB;M{CuO{BvVQ>?	NULzcJB6OjF\|M{e2O\|k>
Rh18	NE\Fe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVGze3JLUUN3ME20NU41KG6P	MWGyNVM{PzZ5OR?=
Rh30	NX\GWnlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTF2IH7N	M4j4SVIyOzN5Nke5
BT-12	NHq3V3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[2cWlEPTB;MkSuO{BvVQ>?	NHW4dGgzOTN\|N{[3PS=>
CHLA-266	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XvfmlEPTB;MT6xJI5O	NF3qPVQzOTN\|N{[3PS=>
TC-71	NXTLNHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfDd2RKSzVyPUS2MlUhdk1?	M1K2PVIyOzN5Nke5
CHLA-9	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zsS2lEPTB;MUWuN{BvVQ>?	NFyxUHAzOTN\|N{[3PS=>
CHLA-10	M1XVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jINWlEPTB;Mz65JI5O	MnfMNlE{Ozd4N{m=
CHLA-258	M{XCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLqTWM2OD1zMD60JI5O	M2\KO\|IyOzN5Nke5
GBM2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPQW\|lKSzVyPUSwMlchdk1?	MVGyNVM{PzZ5OR?=
NB-1643	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTN\|Lkigcm0>	MX:yNVM{PzZ5OR?=
NB-EBc1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2i4eWlEPTB;MkeuNUBvVQ>?	Mnu4NlE{Ozd4N{m=
CHLA-90	MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPnTWM2OD1\|ND61JI5O	MnjrNlE{Ozd4N{m=
CHLA-136	M1O0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3HbW95UUN3ME2xOlIvPiCwTR?=	NHrUSpQzOTN\|N{[3PS=>
NALM-6	NX64bld1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHlOm82UUN3ME2zNk46KG6P	MnPJNlE{Ozd4N{m=
COG-LL-317	M3ziPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M336UGlEPTB;MT6zJI5O	NUmwWJBZOjF\|M{e2O\|k>
RS4;11	NETQTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;DbGlEPTB;M{Wgcm0>	M{LoXlIyOzN5Nke5
MOLT-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoP3TWM2OD16Lk[gcm0>	MUWyNVM{PzZ5OR?=
CCRF-CEM	M2[zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nM[2lEPTB;ND6xJI5O	NXLRb3l5OjF\|M{e2O\|k>
Kasumi-1	NYiyXYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXUTWM2OD1zLkSgcm0>	MoXTNlE{Ozd4N{m=
Karpas-299	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmmxTWM2OD1{MT63JI5O	NYrUS5lFOjF\|M{e2O\|k>
Ramos-RA1	M2r3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P4[WlEPTB;OD6yJI5O	NWLMemxCOjF\|M{e2O\|k>
H838	NH7PWINHfW6ldHnvckBCe3OjeR?=	M1PwbFEh\|ryP	NIn4bWw1QCCq		NIjFTm9qdmS3Y3XzJINmdGxiYYX0c5Bp[We7	NY\0bYpCOjB\|NkSxNVM>
H838	NGfROpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HrW\|AuOyEQvF2=	NWjIfFdoPzJiaB?=		NV3GUJRlcW6mdXPld{Boem:5dHigbY5pcWKrdHnvckBidmRiYYX0c5Bp[We7	MoXvNlAxOjh6NUS=
A549	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYCwMVMh\|ryP	NXLKN4FYPzJiaB?=		M{LhNIlv\HWlZYOg[5Jwf3SqIHnubIljcXSrb36gZY5lKGG3dH;wbIFogQ>?	MkGyNlAxOjh6NUS=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / p-AKT / p-4EBP1 / p-P70S6K / p-PRAS40; PubMed: 24457069 Breast Cancer Res Western blots of 70% confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hours with AZD8055 (0 to 100 nM). Blots were probed with phospho- and total antibodies for mTORC1 and two signalling pathways. In both cell lines mTORC1 and mTORC2 s䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙 p-EGFR / EGFR; PubMed: 25654224 Int J Mol Sci PANC-1 cells were treated with AZD8055 for the indicated hours and EGFR (T/P), AKT (T/P) and ribosomal protein S6 (S6) (T/P) proteins were examined by western-blot; p-FOXO1 / FOXO1 / p-FOXO3a / FOXO3a ; PubMed: 25654224 Int J Mol Sci PANC-1 cells were transfected with FoxO1/FoxO3a siRNAs and treated with AZD8055 for 1 h, then AKT (T/P), FoxO1 (T/P), FoxO3a (T/P) and EGFR (T/P) proteins were examined by western-blot.	24457069 25654224
Immunofluorescence	p-4EBP1 / EIF4E / mTOR; PubMed: 24600487 Int J Clin Exp Med (C) Hoechst 33258 staining of Hep-2 cells after treatment with AZD8055 for 24 hours were shown. The cells were fixed and immunereacted with anti-mTOR antibody followed by incubation with Alexa 488-labeled secondary antibody (C-F). Images were taken by a c䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚،齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙玛W戀ⶰ໯齃礤v 玚W玢Wⶰ໯﫰礌vtЉᔈැ鲬౴᥊疜犈፲Eo狜፲艘ᎂ艘ᎂ⩈̎䥠̌씢痗狠፲붖᎒i變ﱘ﫰﬐먙堘붖᎒狠፲i變ﱘ﫰먰堘ﱘ붖᎒�堞봆᎒릎堘붖᎒i꣩쯟巰痗ꣵ쯟巰痗Љ镴౴嶴痗Љ镨౴ᔈැ竗ᔈැ屷痗W竗尊痗 LC3B / p62 ; PubMed: 30337536 Cell Death Dis Immunofluorescence staining of U87 and U251 GICs, which treated by DMSO, AZD8055 (0.3 μM) and rapamycin (3 μM). The nuclei were stained with DAPI and the antibody against LC3B and p62. Images were captured by laser confocal microscope ( × 400), scale bar 䲧疝Ỵ疞	24600487 30337536
Growth inhibition assay	Cell viability ; PubMed: 29263324 Nat Commun Growth for the indicated cell lines was assessed after 72 h of treatment with AZD8055 (0–250 nM). Results are expressed as a percentage of cell number relative to the DMSO-treated control cells a.	29263324

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	- Collapse Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Formulation: Dissolved in captisol (CyDex, pH 3.0) and diluted to a final captisol concentration of 30% (w/v) Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

- Collapse

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Ethanol	3 mg/mL (6.44 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	COC1=C(CO)C=C(C=C1)C2=NC3=C(C=C2)C(=NC(=N3)N4CCOCC4C)N5CCOCC5C

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (MLN0128)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055